Can a single HIV pill tame the epidemic in africa?
NCT ID NCT04066036
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study follows about 1,000 adults in South Africa and Uganda who are switching to a common HIV treatment called TLD, which combines three drugs into one pill. The goal is to see how effective TLD is in everyday conditions, not just in controlled trials. If the treatment stops working for some people, the researchers will look into possible reasons, such as drug resistance or challenges with taking the medication regularly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A three-drug HIV treatment regimen containing lamivudine, tenofovir, and dolutegravir (known as TLD)
- What this could lead to
- If successful, this could reveal how well TLD works in real-world African settings and help improve HIV care strategies across the region.
- What could go wrong
- As an observational study, it cannot prove cause and effect. Results may be affected by differences in patient adherence or clinic practices, and the findings might not apply to other regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Africa Health Research Institute
Somkele, KwaZulu-Natal, South Africa
-
Mbarara University of Science and Technology
Mbarara, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo
- Long-acting HIV shot studied in patients with severe kidney problems